Novartis/Schering-Plough's Drug Will Replace AstraZeneca's Symbicort as Decision Resources' Clinical Gold Standard by 2012 for the Treatment of Asthma
Posted on: Tuesday, 24 February 2009, 07:00 CST
A Therapy's Effect on Reduction of Exacerbations is the Attribute That Most Influences Physicians' Prescribing Decisions, According to a New Report from Decision Resources
"Physicians we interviewed report that once-daily dosing has the potential to increase patient compliance. Patient compliance is important because asthma is a chronic disease that requires consistent administration of anti-inflammatory drugs to reduce disease severity and limit costly emergency healthcare," said
The new report entitled Asthma: Emerging LABA/ICS Combinations Will Have a Difficult Time Differentiating Themselves from Existing Agents in the Class also finds that a therapy's effect on reducing exacerbations is the attribute that most influences physicians' prescribing decisions in asthma. Based on U.S. and European surveyed physicians, current and emerging therapies have no advantage over sales-leading GlaxoSmithKline's Advair/Seretide/Adoair on this attribute.
About the Report
Asthma: Emerging LABA/ICS Combinations Will Have a Difficult Time Differentiating Themselves from Existing Agents in the Class is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.
The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Natalia Morales Elizabeth Marshall Decision Resources Decision Resources, Inc. 781-296-2691 781-296-2563 nmorales@dresources.com emarshall@dresources.comSOURCE Decision Resources
Source: PR Newswire
Related Articles
- Pivotal Data Show Bronchial Thermoplasty Can Improve Quality of Life and Reduce Asthma Attacks and Emergency Room Visits for Adults with Severe Asthma
- Ottawa Regional Hospital and Healthcare Center Selects Allscripts to Automate and Connect Its Physician Offices, Emergency Department and Home Care Providers
- Law Offices of Howard G. Smith, Representing Investors Who Purchased Quest Resource Corporation and Quest Energy Partners, L.P., Announces Class Action Lawsuit -- QELP, QRCP
- Clostridium Difficile Infection 'Epidemic' Leads to Calls for Emerging Next-Generation Therapies
- GlaxoSmithKline and Theravance Announce Start of Large Phase 2B ICS and LABA Studies for Asthma in the Horizon Programme
- GlaxoSmithKline and Theravance Announce Start of Large Phase 2B ICS and LABA Studies for Asthma in the Horizon Program
- Increasing Disease Prevalence and Emergence of Novel Therapies Will Drive 5% Annual Growth in Type 2 Diabetes Drug Market Through 2016
- Soil Change, Soil Survey, and Natural Resources Decision Making: A Blueprint for Action
- Healing Arts Center Offers Classes, Therapies
- Area Doctor Honored for Emergency Medicine Work; James R. Roberts, M.D., Named One of the 30 Most Influential Physicians in Emergency Medicine
 |
 |
User Comments (0)
RSS Feeds